Expression of androgen receptors in primary breast cancer. - Wikidata - awgldk - TriplyDB

Expression of androgen receptors in primary breast cancer.

Expression of androgen receptors in primary breast cancer.

http://www.wikidata.org/entity/Q43249156

about

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer Targeting androgen receptor in estrogen receptor-negative breast cancer Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer Tamoxifen Resistance: Emerging Molecular Targets Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico Investigation The fate of chemoresistance in triple negative breast cancer (TNBC)Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis Targeting the androgen receptor in prostate and breast cancer: several new agents in development Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.Prolactin/Stat5 and androgen R1881 coactivate carboxypeptidase-D gene in breast cancer cells Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.Prolactin-induced protein is required for cell cycle progression in breast cancer.Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in Prognostication.Androgen receptor expression and breast cancer survival in postmenopausal women.Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients.Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.Treatment options for patients with triple-negative breast cancer Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues.Coagulation factor VII is regulated by androgen receptor in breast cancer.Dietary lignan intake and androgen receptor expression in breast tumors.Triple-negative breast cancer: new perspectives for targeted therapies.Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.Management options in triple-negative breast cancer Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis In-silico identification and functional validation of allele-dependent AR enhancers.Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy.

P2860

Q21195191-48174CBF-2868-4F29-AFE1-D751A61812BC Q21195199-B029F293-D56F-476C-904A-B6D383BC7306 Q24312457-F0487D62-7CC1-4E99-B4A3-52C66F6F0C91 Q24563045-46136B33-F175-48C2-B8D0-4F7F4A59DF0D Q26739969-84495D1A-94E6-452C-861E-733A55D2A6FC Q26770051-251F95A1-4467-4663-9C7E-156CEE4F0F3E Q26775232-B4D5B32D-D0EE-4A0B-B1DB-FE478743C785 Q26823419-21E0DF00-4EFE-45AD-8BE4-496D7607E646 Q27009424-8EE9A204-24D3-4316-A355-693F810BF87C Q33612132-C7CA2F6E-F31D-4111-B635-38217DFF4641 Q33632218-B472012A-C200-4544-B33E-49AFF20BECAC Q33728381-D0BA731D-FA0B-48CF-B6D3-CEFC4424B12A Q33739841-F9C6A92A-937D-4244-A443-F6E39B8285D9 Q33891258-EAC5FDBD-BDE5-48E5-B97D-CB222EE96981 Q33932665-51E3AB98-E702-429B-9C57-0B8E3561569D Q34092016-960412C5-5552-4E15-BB97-3036738B904F Q34164902-C241433E-32BD-4990-B7B0-E0392B2CCE1D Q34228066-5F6382BA-5781-4C1D-B74C-F0561CE48C56 Q34309894-AA8BA192-195B-44ED-8C59-C2CA0B6ACC68 Q34323234-F3C28A03-9275-4FBA-9B80-BEA43AFEED3B Q34331406-29A64C50-F011-4A08-BCEE-E2BEC9780700 Q34476337-44B52596-A934-4BEB-A051-778B1F4E8B45 Q34499512-4BCCC8FF-EFF3-4DDF-B3B1-9950FB0F77D0 Q34512957-5333A7DC-6C19-4CB7-8261-3A5540BE7200 Q34550256-2ACEB533-EBF4-4AE3-B6DC-24B52660C3E8 Q34551559-2AFAC154-811F-4BBB-95B4-141941E8FFBD Q34573232-BAACA2F1-3AC9-40C3-B628-A5FC610E9139 Q34995790-BE8D7EFA-82D0-477C-B92D-D3EFA5C78FF5 Q34995845-9D5F9D4B-286B-4C47-A61E-0183ECC25164 Q35001758-6157B4D6-F8DE-497D-8399-580174D9CB14 Q35088745-28BCA630-0409-4C76-961C-F18C929EE525 Q35155460-91CC19BD-2A01-4D5E-A15C-A14E308F53B8 Q35176984-BF0F0761-5EA0-4171-B723-365909F20584 Q35558993-2BE80470-F954-4690-8386-6A24C1DB1272 Q35651216-D370456F-A291-4191-A74C-80DCC559ACBB Q35668330-34178C79-16C7-457A-B967-0D4F3F21D067 Q35686249-60AE4BD9-6DF7-49A7-BFFC-00B11CC35355 Q35741562-A76776A3-512B-4EFA-8E61-C5DCA43817DD Q35892429-302A1C0F-F02B-49A1-8023-562B2B10DFB9 Q35894728-1FDDCC80-6B9D-4262-9015-F8FA27EB5898

P2860

Expression of androgen receptors in primary breast cancer.

http://www.wikidata.org/entity/Q43249156

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Expression of androgen receptors in primary breast cancer.

@en

Expression of androgen receptors in primary breast cancer.

@nl

type

label

Expression of androgen receptors in primary breast cancer.

@en

Expression of androgen receptors in primary breast cancer.

@nl

prefLabel

Expression of androgen receptors in primary breast cancer.

@en

Expression of androgen receptors in primary breast cancer.

@nl

P1433

Q43249156-6B9B72A1-E938-483F-A9D8-D889DA6A1D28

P1476

Q43249156-7B74DE21-FD8F-42D7-9337-25E3DBF579A8

P2093

Q43249156-70D3304E-8123-4F7A-81BF-ACFC3295A639

Q43249156-7AD9A221-8AEC-447D-A790-8810DDD2ECB0

Q43249156-9BBA6294-BA4E-4EDA-8D01-2487ED71C70A

Q43249156-C5E3EBE4-A2EA-4061-B86B-7F8968A8AE76

Q43249156-E8EBF8EA-30F2-430A-9B59-14FE1F9A77A4

Q43249156-EC250572-68CA-4B02-9A4C-816D6A6FED08

Q43249156-EF9DE642-0E4B-48AD-9B58-379B79995C8E

Q43249156-F621AB0C-3212-4599-89EF-573AA80DFBA7

P2860

Q43249156-1B146051-F027-4E7C-9700-311BDC2D84AA

Q43249156-1D8F8F89-5B59-42CC-BE5F-53DB8DDE6D3A

Q43249156-2E278FEA-DEC3-4ED8-9E3B-8B7919A8E429

Q43249156-3084F5A9-9F98-4327-A44D-E71D4BC9F0A9

Q43249156-36B33855-7EDF-4507-A5DD-7C96ED8EB202

Q43249156-4980360E-3646-4EFE-AA39-499CAE235FCC

Q43249156-5160D28B-37E4-4554-B457-7F206A07C8A8

Q43249156-56CF5C17-973E-4567-9220-6F8D3DE4B1B8

Q43249156-70F72DC2-5DCF-4352-B86C-99C28B35CC73

Q43249156-7442028E-E197-459D-8A0D-DE9D949C9416

P304

Q43249156-D5DA0585-5315-4061-AD9A-63E42244616E

P31

Q43249156-846DD693-5B6D-4C81-8811-F08EDA6165BF

P356

Q43249156-AED310CD-6282-4AB0-B861-79493F767DB3

P433

Q43249156-2D17F91E-6080-4C30-8975-CDE593BC324C

P478

Q43249156-5952CBA6-64EB-4A63-A974-3D12CE32A1C4

P577

Q43249156-E7C19253-A89A-4566-B56B-542641ECEA07

P5875

Q43249156-A76CA280-B297-4EAA-980C-44476CEFB332

P698

Q43249156-C008292B-24B2-4F81-864C-EF30DC99827B

P356

P1433

Annals of Oncology

P1476

Expression of androgen receptors in primary breast cancer.

@en

P2093

B-W Park

http://www.w3.org/2001/XMLSchema#string

H S Park

http://www.w3.org/2001/XMLSchema#string

J H Lee

http://www.w3.org/2001/XMLSchema#string

J Koo

http://www.w3.org/2001/XMLSchema#string

J-H Kim

http://www.w3.org/2001/XMLSchema#string

K S Lee

http://www.w3.org/2001/XMLSchema#string

S Park

http://www.w3.org/2001/XMLSchema#string

S-Y Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2009

Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.

Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.

Targeted therapies in breast cancer: where are we now?

Therapeutic strategies for triple-negative breast cancer.

Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.

Novel agents on the horizon for cancer therapy.

P304

488-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP510

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38065409

http://www.w3.org/2001/XMLSchema#string

P698

19887463

http://www.w3.org/2001/XMLSchema#string